PEDIATRICS Vol. 94 No. 3 September 1994, pp. 385-389
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Samuel, R.
Right arrow Articles by Zaizov, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Samuel, R.
Right arrow Articles by Zaizov, R.

Aminohydroxy Propylidene Bisphosphonate (APD) Treatment Improves the Clinical Skeletal Manifestations of Gaucher's Disease

Ruth Samuel MD1, Socrates E. Papapoulos MD1, Uri A. Liberman MD, PhD1, Kalman Katz MD2, Zvi Yosipovitch MD2, and Rina Zaizov MD3

1 Unit of Metabolic Diseases, Beilinson Medical Center, Petah Tiqva and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
2 Department of Orthopedics, Beilinson Medical Center, Petah Tiqva and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
3 Sambur Center of Pediatric Hematology/Oncology, Beilinson Medical Center, Petah Tiqva and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Objective. To evaluate the long-term effects and safety of aminohydroxy propylidene bisphosphonate (APD) treatment on the frequency and severity of the clinical skeletal manifestations of Gaucher's disease.

Methodology. Five adolescents who suffered from recurrent bone crisis episodes and atraumatic bone fractures due to Gaucher's disease were treated with APD for 14 to 83 months.

Results. During the 6 years before treatment, the patients suffered from 6 to 17 bone crisis episodes, or 1 to 2.8 episodes per patient per year. Three patients were free from bone crisis episodes during 14 to 32 months of ADP treatment, while two patients had two such episodes during 60 and 83 months of APD treatment (these represent a decrease in bone crisis episodes from 1 and 2.8 per year to 0.4 and 0.3 per year, respectively). Although four patients suffered from 1 to 3 atraumatic bone fractures during the 6 years preceding treatment (a total of 10 fractures), only one patient sustained a fracture on APD treatment (total of 219 months of treatment). Using APD was not associated with clinical side effects, biochemical aberrations, significant changes in liver and kidney function, or changes in serum levels of the hormones regulating mineral metabolism. In all patients, a band-like metaphyseal sclerosis appeared on radiography of the long bone. However, APD did not interfere with bone growth.

Conclusions. The marked clinical improvement in the clinical skeletal manifestations of Gaucher's disease and the absence of toxic side effects in adolescent patients treated with APD support previous findings in three adult patients on the efficacy of APD and indicate possibilities for its use in inducing prolonged remissions in affected patients.

Submitted on July 29, 1993
Accepted on February 15, 1994




This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
S. Agarwala, D. Jain, V. R. Joshi, and A. Sule
Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study
Rheumatology, March 1, 2005; 44(3): 352 - 359.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
R J Wenstrup, M Roca-Espiau, N J Weinreb, and B Bembi
Skeletal aspects of Gaucher disease: a review
Br. J. Radiol., May 24, 2002; 75(90001): A2 - 12.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
H. J. Mankin, D. I. Rosenthal, and R. Xavier
Gaucher Disease : New Approaches to an Ancient Disease
J. Bone Joint Surg. Am., May 1, 2001; 83(5): 748 - 763.
[Full Text] [PDF]

Home page
 CLIN PEDIATRHome page
T. Srivastava and U. S. Alon
Bisphosphonates: From Grandparents to Grandchildren
Clinical Pediatrics, November 1, 1999; 38(12): 687 - 702.
[Abstract] [PDF]

Home page
 PediatricsHome page
A. N. Lteif and D. Zimmerman
Bisphosphonates for Treatment of Childhood Hypercalcemia
Pediatrics, October 1, 1998; 102(4): 990 - 993.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
G. Ciana, M. Cuttini, and B. Bembi
Short-Term Effects of Pamidronate in Patients with Gaucher's Disease and Severe Skeletal Involvement
N. Engl. J. Med., September 4, 1997; 337(10): 712 - 712.
[Full Text]

Home page
 Arch. Dis. Child.Home page
J. Allgrove
Biphosphonates
Arch. Dis. Child., January 1, 1997; 76(1): 73 - 75.
[Full Text]